Chongsrisawat Voranush, Poovorawan Yong
Viral Hepatitis Research Unit, Department of Pediatrics, Chulalongkorn University & Hospital, Bangkok, Thailand.
Indian J Pediatr. 2002 Feb;69(2):149-54. doi: 10.1007/BF02859377.
Hepatitis B and C virus (HBV and HCV) infections present an important health problem causing significant morbidity and mortality on a worldwide scale. The younger the subjects infected, the higher the risk predisposing to progression towards chronic infection. Treatment of chronic HBV and HCV infections is aimed at reducing hepatic inflammation and thus improving the symptoms, decreasing the likelihood of long-term sequelae such as hepatocellular carcinoma, and increasing the survival rate. Interferon accelerates the spontaneous course of chronic HBV infection in children with greater disease activity and lower levels of replication. There is limited information on the use of lamivudine and its long-term benefit in children with chronic HBV infection. The response of combination therapy with IFN and ribavirin in children with chronic HCV infection is still under investigation. The long-term clinical and virological effects of various drugs used in chronic HBV and HCV infections on children remain to be evaluated.
乙型肝炎病毒和丙型肝炎病毒（HBV和HCV）感染是一个重要的健康问题，在全球范围内导致了显著的发病率和死亡率。感染的受试者年龄越小，发展为慢性感染的风险就越高。慢性HBV和HCV感染的治疗旨在减轻肝脏炎症，从而改善症状，降低诸如肝细胞癌等长期后遗症的可能性，并提高生存率。干扰素可加速疾病活动度较高且复制水平较低的慢性HBV感染儿童的自然病程。关于拉米夫定在慢性HBV感染儿童中的使用及其长期益处的信息有限。IFN和利巴韦林联合治疗慢性HCV感染儿童的疗效仍在研究中。用于慢性HBV和HCV感染的各种药物对儿童的长期临床和病毒学影响仍有待评估。
